Synthetic lipopeptide analogs of bacterial lipoprotein are potent polyclonal activators for murine B lymphocytes
- PMID: 3874908
Synthetic lipopeptide analogs of bacterial lipoprotein are potent polyclonal activators for murine B lymphocytes
Abstract
The lipoprotein from the outer membrane of Escherichia coli and other Enterobacteriaceae is a potent polyclonal activator for B lymphocytes. To determine the molecular structure responsible for the biologic activity of lipoprotein, a well-defined series of analogs of its N-terminal part was synthesized: S-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-cysteine, -cysteine methyl ester, -cysteinyl-serine, -cysteinyl-seryl-serine, -cysteinyl-seryl-seryl-asparagine, and -cysteinyl-seryl-seryl-asparaginyl-alanine. All compounds were tested for mitogenic activity toward spleen cells from BALB/c, LPS-non-responder C3H/HeJ, and congenitally athymic C3H/Tif/Bom/nu/nu mice, measuring the incorporation of [3H]thymidine into DNA. Lymphocyte activation was confirmed by determination of the incorporation of [3H]uridine into RNA and [3H]leucine into protein. The synthetic lipopeptides were also investigated for their ability to stimulate B lymphocytes into immunoglobulin secretion, as shown by a hemolytic plaque assay. Throughout our studies, the compounds carrying two to five amino acids exhibited strong stimulation activity toward B lymphocytes comparable to native lipoprotein. In contrast, products containing only one amino acid, cysteine or cysteine methyl ester, were only marginally active, indicating that to obtain full biologic activity the presence of the hydrophilic dipeptide structure is necessary. All compounds exhibited only a marginal effect on thymocytes. Thus, a series of defined synthetic fragments of a bacterial outer membrane component exhibits a pronounced mitogenic and polyclonally stimulating activity towards B lymphocytes. The substances will be valuable tools for more detailed investigations on the molecular mechanisms of B cell activation.
Similar articles
-
Comparison of biologic activities of synthetic lipopentapeptide analogs of bacterial lipoprotein in mice.Mol Biother. 1991 Mar;3(1):46-50. Mol Biother. 1991. PMID: 2069759
-
A synthetic analogue of Escherichia coli lipoprotein, tripalmitoyl pentapeptide, constitutes a potent immune adjuvant.J Immunol. 1986 Oct 15;137(8):2676-81. J Immunol. 1986. PMID: 3531339
-
Synthetic analogues of the N-terminal lipid part of bacterial lipoprotein are B-lymphocyte mitogens in vitro and in vivo.Immunobiology. 1983 Jul;165(1):27-35. doi: 10.1016/S0171-2985(83)80044-8. Immunobiology. 1983. PMID: 6350164
-
B-lymphocyte mitogenicity in vitro of a synthetic lipopeptide fragment derived from bacterial lipoprotein.Hoppe Seylers Z Physiol Chem. 1982 Jul;363(7):767-70. Hoppe Seylers Z Physiol Chem. 1982. PMID: 6751983
-
Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.Behring Inst Mitt. 1984 May;(74):157-73. Behring Inst Mitt. 1984. PMID: 6383322 Review.
Cited by
-
Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides.J Med Chem. 2010 Apr 22;53(8):3198-213. doi: 10.1021/jm901839g. J Med Chem. 2010. PMID: 20302301 Free PMC article.
-
The second and third amino acids of Pam2 lipopeptides are key for the proliferation of cytotoxic T cells.Innate Immun. 2018 Jul;24(5):323-331. doi: 10.1177/1753425918777598. Epub 2018 May 31. Innate Immun. 2018. PMID: 29848176 Free PMC article.
-
Lipopeptides activate Gi-proteins in dibutyryl cyclic AMP-differentiated HL-60 cells.Biochem J. 1993 Nov 15;296 ( Pt 1)(Pt 1):245-51. doi: 10.1042/bj2960245. Biochem J. 1993. PMID: 8250850 Free PMC article.
-
Interaction of Mycoplasma hominis PG21 with Human Dendritic Cells: Interleukin-23-Inducing Mycoplasmal Lipoproteins and Inflammasome Activation of the Cell.J Bacteriol. 2017 Jul 11;199(15):e00213-17. doi: 10.1128/JB.00213-17. Print 2017 Aug 1. J Bacteriol. 2017. PMID: 28559291 Free PMC article.
-
Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.Br J Cancer. 2005 Apr 25;92(8):1421-9. doi: 10.1038/sj.bjc.6602526. Br J Cancer. 2005. PMID: 15812545 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous